Login
Subscribe
Cross-Resistance: One Cancer Therapy Can Undermine the Next
Cross-Resistance: One Cancer Therapy Can Undermine the Next
Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.
Targeted cancer therapy may jeopardize the effectiveness of subsequent immunotherapy by reducing dendritic cell numbers and activation, according to study of mice and patient samples.
immunotherapy, immunology, cell & molecular biology
Contributors
The Scientist | Jul 13, 2020 | 3 min read
Meet some of the people featured in the July/August 2020 issue of The Scientist.
Novel DNA-Sensing Pathway Found in Human Cells, Absent in Mice
Catherine Offord | Jan 24, 2020 | 4 min read
This previously unknown mechanism for spotting foreign genetic material in the cytoplasm launches antiviral defenses even when the well-known immune mediator STING is absent.
Natural Killer Cells Prove Effective as a CAR Therapy in Mice
Katarina Zimmer | Jul 6, 2018 | 4 min read
Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.
A T-Cell Tweak Combats Advanced Breast Cancer
Ashley Yeager | Jun 5, 2018 | 2 min read
The immunotherapy eliminated a woman’s metastatic lesions and kept her disease-free for two years.
Yvonne Saenger: Immunotherapy Pioneer
Jef Akst | Apr 1, 2015 | 3 min read
Assistant Professor, Department of Medicine, Columbia University. Age: 41
Cancer Immunotherapist
Jef Akst | Mar 31, 2015 | 1 min read
Scientist to Watch Yvonne Saenger explains recent advances in using biomarkers to identify cancer patients who might benefit most from immunotherapy.